Company Willow Biosciences Inc. Canadian Securities Exchange
Equities
WLLW
CA97111B4047
Pharmaceuticals
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CAD | -.--% | -.--% | -.--% |
Business Summary
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research and Development
100.0
%
| 1 | 77.2 % | 1 | 100.0 % | +84.86% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 77.2 % | 1 | 100.0 % | +84.86% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chris Savile
CEO | Chief Executive Officer | - | 11/04/19 |
Travis Doupe
DFI | Director of Finance/CFO | - | 11/04/19 |
Trish Choudhary
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/19 |
Simon Hickling
PRN | Corporate Officer/Principal | - | - |
Sony Gill
SEC | Corporate Secretary | 48 | 11/04/19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jim Lalonde
CHM | Chairman | 63 | 20/02/23 |
Donald Archibald
BRD | Director/Board Member | 63 | 11/04/19 |
Director/Board Member | 51 | 11/04/19 | |
Raffi Asadorian
BRD | Director/Board Member | 54 | 10/05/23 |
Chris Savile
CEO | Chief Executive Officer | - | 11/04/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 127,345,288 | 92,635,973 ( 72.74 %) | 0 | 72.74 % |
Company contact information
Willow Biosciences, Inc.
1201 5th Street South West Suite 202
T2R 0Y6, Calgary
+
http://www.willowbio.comSector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
+2.87% | 94.22B | |
-4.08% | 37.76B | |
-13.67% | 32.5B | |
+73.38% | 27.75B | |
-11.63% | 16.13B | |
-0.67% | 14.19B | |
-11.67% | 11.42B | |
+190.36% | 11.06B | |
-52.61% | 9.09B |
- Stock Market
- Equities
- WLLW Stock
- WLLW Stock
- Company Willow Biosciences Inc.